Seattle Genetics is in the limelight once again for coming out with a groundbreaking cancer drug and a visit from the VP Joe Biden. The drug company is shining a new hope for lymphoma patients and aiming to expand the scope of their drug’s medical capabilities.
Ever since their recent discovery, Seattle Genetics seized to be just another cancer research center. They now have a commercialized drug, Adcetris, which they believe can cure a number of cancer-related ailments. Currently, the drug has proven efficient in improving the quality of life of patients with lymphoma disease.
According to the company’s CEO, Clay Siegall, Adcetris is undergoing advanced clinical trials for about 70 different lymphoma strains. The cancer research center is adding Adcetris to a cocktail of drugs that they hope will be the answer for the new lymphoma case, Hodgkin Lymphoma. When these trials work, it will be a major break for the company, and of course a brilliant addition to Seigall’s already shining resume.
Adcetris has already raked Seattle Genetics untold profits; a total of $226 million in US and Canada alone. For 2016, sales are projected to range between 225$-275$ in the said countries. Adcetris is grossing globally as well through their partner company Takeda Pharmaceutical, that’s responsible for distribution. That’s not all, Seattle Genetics is already running advanced trials for another drug, 33A, to be used in acute myeloid leukemia treatment. The cancer research center also has two drugs for breast and bladder cancer treatment.
About Clay Siegall
Clay Siegall holds the roles of CEO, President and board chairman at Seattle Genetics. Before this, Mr. Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Center, the National Cancer Institute, and National Institute of Health in America. In 2014, he joined the leadership board of Ultragenyx and later on a board director at Mirna Therapeutics and Alder Bio-Pharmaceuticals. Clay Seagall holds a degree in Zoology from the University of Maryland and later attained his Ph.D. in Genetics at George Washington University.
Clay Siegall co-founded Seattle Genetics and has worked with the company for over 19 years. In this time, he has received a number of recognitions like getting Adcetris approved by the FDA and putting Seattle Genetics on the map as a top cancer research center.